The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000607370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
21/04/2026
Date registered
Help: Date registered
15/05/2026
Date last updated
Help: Date last updated
15/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
15/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Automated insulin delivery in people with type 2 diabetes undergoing elective hip or knee arthroplasty
Scientific title
A randomised controlled trial of the Omnipod 5™ automated insulin delivery system on perioperative glycaemic management in patients with type 2 diabetes mellitus undergoing elective hip or knee arthroplasty surgery
Additional trial identifiers [1] 316348 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Type 2 diabetes mellitus 341599 0
Osteoarthritis 341685 0
Knee arthroplasty 341686 0
Hip arthroplasty 341687 0
Condition category
Condition code
Musculoskeletal 337675 337675 0 0
Osteoarthritis
Metabolic and Endocrine 337676 337676 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Intervention delivery:
Participants randomised to the intervention group will use the OmniPod 5™ automated insulin delivery (AID) system integrated with the FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor.
The OmniPod 5 system is a tubeless, wearable insulin pump (pod) worn on the body (typically arm or abdomen) that delivers rapid-acting insulin continuously for up to three days per pod. The system automatically adjusts basal insulin delivery every five minutes based on real-time CGM glucose measurements. Participants administer prandial insulin using pre-set meal bolus options (small, medium, or large). Rapid-acting insulin (NovoRapid® or Humalog®) is used throughout the study.
Device replacement:
Participants replace the OmniPod 5 pod themselves approximately every three days for the duration of the intervention. The CGM sensor is replaced according to manufacturer instructions. Participants receive education and written instructions to support independent device changes.
Run-in period
Participants complete a two-week run-in period prior to formal intervention commencement. During this period, participants wear the CGM sensor and continue usual diabetes care to assess baseline glycaemic patterns, ensure device familiarity, and confirm study eligibility prior to initiation of OmniPod 5.
Following the run-in period, participants commence OmniPod 5 approximately three to four weeks prior to elective hip or knee arthroplasty and continue use for approximately ten weeks, including the pre-operative period, hospital admission (including surgery), and post-discharge period.

Education and training
The intervention is delivered individually.

Initial education:
One to two individual face-to-face sessions at randomisation (approximately 60 minutes per session) with a credentialled diabetes clinician. These sessions include device setup, insulin parameter configuration, troubleshooting, and safety education.

Dietitian education:
A face-to-face session with a dietitian (approximately 30 minutes) occurs during the initial education period. This session focuses on carbohydrate awareness, meal bolus selection (small, medium, large), peri-operative nutrition considerations, and use of the OmniPod 5 system in relation to food intake.


Early follow-up:
A supervised pod change within the first few days of initiation (approximately 20 to 30 minutes) to ensure correct technique and reinforce education.

Ongoing review:
Follow-up reviews at scheduled study visits (pre-operative, hospital admission, and post-discharge), each lasting approximately 20 to 30 minutes, with additional contacts provided via face-to-face, telehealth, or telephone as clinically indicated.

Setting
The intervention is delivered across multiple settings, including:

Outpatient clinical trials unit (education, initiation, and follow-up),
Participant’s home environment (daily system use),
Hospital inpatient setting during admission for surgery, and
Virtual platforms or telephone for interim support.

Participants may continue using the OmniPod 5 system during hospital admission unless clinically contraindicated.
Adherence monitoring
Adherence will be monitored using objective device-generated data. Measures include CGM wear time, percentage of time the OmniPod 5 system operates in automated insulin delivery mode, and the number of days with equal to or more than 70 percent valid CGM data. Device data will be uploaded and reviewed at scheduled study visits and during hospital admission.
Intervention code [1] 333841 0
Treatment: Devices
Description of the comparator or control
Comparator/Control Group:
Participants randomised to the control group will receive usual diabetes care, as determined by their treating clinicians. This may include oral glucose-lowering medications, non-insulin injectable therapies, and/or insulin administered by injection, with self-monitoring of blood glucose as per routine practice.
In addition, control participants will wear a masked continuous glucose monitoring device (FreeStyle Libre Pro iQ) for research data collection from two weeks prior to surgery until the end of the study (week 10), including during hospital admission and the post-discharge period. Masked CGM data will not be visible to participants or clinicians and will not be used to guide clinical management.

Usual care is delivered by:
the participant’s usual diabetes care providers (e.g. general practitioners, endocrinologists),
hospital medical and endocrinology teams during the peri-operative admission, and
nursing staff experienced in routine inpatient diabetes management.

All care providers are trained clinicians with expertise in standard diabetes management but do not deliver automated insulin delivery or real-time CGM–guided treatment.

Usual care is delivered on an individual basis, consistent with routine practice, through:
standard outpatient diabetes care, pre-admission clinics, inpatient ward-based care during admission for surgery, and post-discharge follow-up as clinically indicated.
No additional intervention-specific education or technology training is provided beyond standard care.

Duration: approximately 10 weeks per participant, from randomisation to end of study follow-up
Masked CGM wear: continuous wear from 2 weeks prior to surgery until week 10
Clinical contact: as per routine clinical care and scheduled study visits
There is no fixed session schedule beyond usual care and study assessments.

Usual care is delivered across:
- participant’s home (routine diabetes self-management and self-monitoring of blood glucose),
- outpatient clinics and study site visits,
- hospital inpatient setting during surgery admission.

Adherence in the usual care group is monitored through:
masked CGM data, including wear time and completeness of data,
study diaries documenting medications and self-monitoring of blood glucose,
scheduled CGM uploads at study visits and hospital admission.

No prompts or reminders beyond routine clinical follow-up are provided, maintaining the integrity of the usual care comparator.
Control group
Active

Outcomes
Primary outcome [1] 345162 0
Percentage of time in glucose target range (3.9–10.0 mmol/L) measured by CGM during the two weeks immediately prior to surgery.
Timepoint [1] 345162 0
Difference in the percentage of time spent in glucose target range (3.9–10.0 mmol/L) between the intervention and usual care groups during the two weeks immediately prior to elective hip or knee arthroplasty surgery.
Secondary outcome [1] 460737 0
Time in range (TIR): % time 3.9–10.0 mmol/L (assessed for each analysis period: pre-operative 2 weeks prior to admission; hospital admission day of surgery to discharge; post-discharge discharge to end of study; via CGM data download).
Timepoint [1] 460737 0
Pre-operative period: Two weeks immediately prior to surgery Peri-operative period: From day of hospital admission to discharge Post-operative period: From hospital discharge to end of study follow-up (week 10)
Secondary outcome [2] 461011 0
Number of severe hypoglycaemia events, defined as events with altered mental and/or physical functioning requiring assistance from another person for recovery, irrespective of glucose value.
Timepoint [2] 461011 0
Pre-operative period: Two weeks immediately prior to surgery Peri-operative period: From day of hospital admission to discharge Post-operative period: From hospital discharge to end of study follow-up (week 10)
Secondary outcome [3] 461012 0
Time above range (TAR): % time >10.0 mmol/L
Timepoint [3] 461012 0
Pre-operative period: Two weeks immediately prior to surgery Peri-operative period: From day of hospital admission to discharge Post-operative period: From hospital discharge to end of study follow-up (week 10)
Secondary outcome [4] 461013 0
Mean sensor glucose (mmol/L)
Timepoint [4] 461013 0
Pre-operative period: Two weeks immediately prior to surgery Peri-operative period: From day of hospital admission to discharge Post-operative period: From hospital discharge to end of study follow-up (week 10)
Secondary outcome [5] 461014 0
Glycaemic variability: coefficient of variation (%CV)
Timepoint [5] 461014 0
Pre-operative period: Two weeks immediately prior to surgery Peri-operative period: From day of hospital admission to discharge Post-operative period: From hospital discharge to end of study follow-up (week 10)
Secondary outcome [6] 461015 0
Change in HbA1c
Timepoint [6] 461015 0
Comparing baselines HbA1c with study end/week 10 HbA1c
Secondary outcome [7] 461016 0
Length of hospital stay (days)
Timepoint [7] 461016 0
Assessed from admission to discharge
Secondary outcome [8] 461017 0
Post-operative infection (Yes/No)
Timepoint [8] 461017 0
Assessed during admission and follow-up to end of study
Secondary outcome [9] 461018 0
Surgical wait time (days from listing/randomisation to surgery; and proportion of wait time)
Timepoint [9] 461018 0
Assessed to day of surgery
Secondary outcome [10] 461019 0
Surgery cancellation (yes/no; number of cancellations; proportion cancelled)
Timepoint [10] 461019 0
Assessed end of study
Secondary outcome [11] 461020 0
Hospital readmission - yes/no; number of readmissions
Timepoint [11] 461020 0
Assessed from discharge to end of study
Secondary outcome [12] 461021 0
Intervention adherence
Timepoint [12] 461021 0
study end/week 10
Secondary outcome [13] 461022 0
Diabetes distress
Timepoint [13] 461022 0
study end/week 10
Secondary outcome [14] 461023 0
Diabetes medication satisfaction
Timepoint [14] 461023 0
study end/week 10
Secondary outcome [15] 461024 0
Diabetes technology satisfaction
Timepoint [15] 461024 0
study end/week 10
Secondary outcome [16] 461025 0
System usability
Timepoint [16] 461025 0
study end/week 10
Secondary outcome [17] 461026 0
Health service and hospital resource use (counts of diabetes-related contacts/presentations as defined in the protocol
Timepoint [17] 461026 0
assessed to end of study
Secondary outcome [18] 461027 0
Patient experience
Timepoint [18] 461027 0
study end/week 10

Eligibility
Key inclusion criteria
Adults aged more than or equal to 18 years
Confirmed diagnosis of type 2 diabetes mellitus
HbA1c >7.0% (53 mmol/mol) within 3 months of screening or measured at screening
Scheduled to undergo elective hip or knee arthroplasty surgery
Estimated glomerular filtration rate (eGFR > 30 mL/min/1.73 m²)
On a stable diabetes treatment regimen (oral agents, non-insulin injectables and/or insulin) for at least 6 weeks prior to screening
Willingness and ability to use diabetes technology and comply with study procedures
Able to provide written informed consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Diagnosis of type 1 diabetes
Total daily insulin dose >60 units/day
Current use of insulin pump therapy
Severe renal impairment (eGFR 1000 mg/day ascorbic acid (vitamin C)
Any condition that, in the investigator’s opinion, would make participation unsafe or interfere with study outcomes

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment is maintained through centralised computer-generated randomisation via REDCap, with allocation revealed only after enrolment and baseline assessment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A computer-generated randomisation sequence with permuted blocks and 1:1 allocation, stratified by age and baseline HbA1c, generated by an independent statistician and implemented via REDCap.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Analyses will follow the intention-to-treat principle. The primary outcome will be compared between groups using ANCOVA adjusted for baseline values and stratification variables. Secondary outcomes will be analysed using appropriate regression or categorical methods, with results reported with 95% confidence intervals.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29420 0
Austin Health - Austin Hospital - Heidelberg
Recruitment hospital [2] 29421 0
Austin Health - Heidelberg Repatriation Hospital - Heidelberg West
Recruitment postcode(s) [1] 45739 0
3084 - Heidelberg
Recruitment postcode(s) [2] 45740 0
3081 - Heidelberg West

Funding & Sponsors
Funding source category [1] 320951 0
Commercial sector/Industry
Name [1] 320951 0
Insulet Corporation - in-kind product support
Country [1] 320951 0
United States of America
Funding source category [2] 321671 0
Commercial sector/Industry
Name [2] 321671 0
Abbott Diabetes Care in-kind product support
Country [2] 321671 0
United States of America
Funding source category [3] 321672 0
University
Name [3] 321672 0
University of Melbourne - in-kind support as part of PhD Candidature
Country [3] 321672 0
Australia
Primary sponsor type
Hospital
Name
Austin Health
Address
Country
Australia
Secondary sponsor category [1] 323647 0
Commercial sector/Industry
Name [1] 323647 0
Abbott Diabetes Care
Address [1] 323647 0
Country [1] 323647 0
United States of America
Secondary sponsor category [2] 324541 0
Commercial sector/Industry
Name [2] 324541 0
Insulet Corporation - In-kind support product only
Address [2] 324541 0
Country [2] 324541 0
United States of America

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319489 0
Austin Health Human Research Ethics Committee
Ethics committee address [1] 319489 0
Ethics committee country [1] 319489 0
Australia
Date submitted for ethics approval [1] 319489 0
29/05/2025
Approval date [1] 319489 0
11/03/2026
Ethics approval number [1] 319489 0
HREC/24360/Austin-2025

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147490 0
Prof Elif Ekinci
Address 147490 0
Centre for Research and Education in Diabetes and Obesity (CREDO), Level 1, 300 Waterdale Road, Heidelberg Heights VIC 3081, Australia.
Country 147490 0
Australia
Phone 147490 0
+61 394962250
Fax 147490 0
Email 147490 0
Contact person for public queries
Name 147491 0
Mrs Simone Patterson
Address 147491 0
Centre for Research and Education in Diabetes and Obesity (CREDO), Level 1, 300 Waterdale Road, Heidelberg Heights VIC 3081, Australia.
Country 147491 0
Australia
Phone 147491 0
+61394965578
Fax 147491 0
Email 147491 0
Contact person for scientific queries
Name 147492 0
Mrs Simone Patterson
Address 147492 0
Centre for Research and Education in Diabetes and Obesity (CREDO), Level 1, 300 Waterdale Road, Heidelberg Heights VIC 3081, Australia.
Country 147492 0
Australia
Phone 147492 0
+61394965578
Fax 147492 0
Email 147492 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Primary outcome(s)
• Safety data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Health economic analyses
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: Requests for access to de-identified individual participant data can be made by contacting the trial custodian by email. Requests will be reviewed on a case-by-case basis and are subject to ethics requirements and a data sharing agreement.
Email: [email protected]


Are there extra considerations when requesting access to individual participant data?
Yes: Access to de-identified individual participant data is subject to investigator review, ethics requirements, and execution of a data sharing agreement. Data will only be shared for scientifically appropriate purposes following publication of the primary results.



What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Informed consent form    Omnipod5 study PICF V1.4 dated 13.11.2025_TC_Site Specific_Clean.pdf
Ethical approval    HREC_24360_Austin-2025 Approval.pdf
Other    CTN Acknowledgement CT-2025-CTN-05992-1 v1 - Acknowledged.pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.